USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ANJIN GROUP, INC.
City: COCKEYSVILLE
State: MD
Zip+4: 21030 2202
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $567,216.00 4

Award List:

An IL-2 Receptor Targeted Toxin with Reduced VLS

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Johanna C. Vanderspek
Award Amount: $144,786.00
Abstract:
DESCRIPTION (provided by applicant): Well over a decade ago the first diphtheria toxin-based fusion protein toxin, DAB389IL-2 (Ontak(R)) was in development as the first of a new class of receptor specific therapeutic agent. This fusion protein gained FDA approval five years ago for the treatment of… More

Modified Diphtheria Toxin IL-7 Fusion Toxins

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Johanna C. Vanderspek
Award Amount: $152,141.00
Abstract:
DESCRIPTION (provided by applicant): Sweeney et al. (1998) originally reported the construction of DAB389IL-7, a fusion protein based on diphtheria toxin (DT), and proposed that this fusion protein could be employed as a therapeutic agent for hematological malignancies, including acute lymphoblastic… More

Generation of a Modified DT_IL3 Fusion Toxin

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $122,830.00
Abstract:
DESCRIPTION (provided by applicant): A number of protein fusion toxins, composed of the diphtheria toxin (DT) toxophore and a targeting ligand, have been assembled and tested in Phase I clinical trials for the treatment of leukemias. To date, the only FDA approved protein fusion toxin is ONTAK.… More

Further Analysis of a VLS Modified IL-2 Receptor Targeted Toxin

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $147,459.00
Abstract:
DESCRIPTION (provided by applicant): The project seeks to further the development of a series of diphtheria toxin mutants which, when employed in the construction of protein fusion toxins, display reduced induction of leakage through vascular endothelial c ell monolayers. The goals of this Phase I… More